Lowell General Hospital
11
0
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
40%
4 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Efficacy and Safety of 500mg of Fulvestrant
Role: collaborator
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
Role: collaborator
Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease
Role: lead
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Role: collaborator
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
Role: collaborator
The MASS COMM Post-Randomization Phase Cohort Study
Role: collaborator
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Role: collaborator
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
Role: collaborator
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Role: collaborator
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
Role: collaborator
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Role: collaborator
All 11 trials loaded